Chiropractic News

September 2008

Article Tools

Chiropractic News from Business Wire

A Pipeline Insight of the Cancer R&D Market: With a Focus on Lung, Brain, Head, Neck and Thyroid Tumors

Research and Markets (http://www.researchandmarkets.com/research/820277/pipeline_insight) has announced the addition of the "Pipeline Insight: Cancer Overview - Lung, Brain, Head and Neck, Thyroid" report to their offering.

In 2008, the six tumor types covered in this report are forecast to account for over 666,000 new cases of cancer, obviously representing an enormous market potential. However, it is the higher-incidence tumor types that continue to attract drug developers, with lower-incidence cancers potentially suffering due to unfulfilled unmet needs via a lack of R&D activity.

Scope

- Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor types

- Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions

- Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication for six tumor types

- Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs

Highlights of this title

A low level of interest from drug developers means unmet needs in the SCLC, mesothelioma, primary brain and thyroid cancer markets are likely to remain unfulfilled. Drug developers should realize that despite being low-incidence tumor types, high unmet needs could result in significant financial rewards and a foothold in the market to build upon.

Erbitux (cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono) shows the most promise in the current NSCLC pipeline. Recent clinical trial results mean Erbitux may become a viable option in the first-line treatment of NSCLC, particularly for those patients ineligible for Avastin (bevacizumab; Genentech/Roche) therapy.

Vectibix (panitumumab; Amgen) and

zalutumumab (HuMax-EGFR; Genmab/Medarex) show great promise to compete with Erbitux in the head and neck cancer market, particularly due to potential toxicity advantages that fully human monoclonal antibodies may have.

Key reasons to purchase this title

- Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2017 and Datamonitor drug assessment

- Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to provide satisfaction

- Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products

Key Topics Covered:

- Executive Summary

- Pipeline Overview and Dynamics

- R&D Approach

- Non-Small Cell Lung Cancer

- Small Cell Lung Cancer

- Mesothelioma

- Primary Brain Cancer